CAPPED REVERSE BONUS ZERTIFIKAT - FRESENIUS Share Price

Certificat

DE000GQ2XR40

Real-time BOERSE MUENCHEN 17:11:02 11/07/2024 BST
26.92 EUR +0.19% Intraday chart for CAPPED REVERSE BONUS ZERTIFIKAT - FRESENIUS
Current month-0.52%
1 month+5.95%
Date Price Change
11/07/24 26.92 +0.19%
10/07/24 26.87 -0.19%
09/07/24 26.92 +0.37%
08/07/24 26.82 +0.07%
05/07/24 26.8 -0.33%

Real-time BOERSE MUENCHEN

Last update July 11, 2024 at 05:11 pm

More quotes

Static data

Product typeBonus- und Teilschutz-Zertifikate
Buy / SellPUT
Underlying FRESENIUS SE & CO. KGAA
Issuer Goldman Sachs
WKN GQ2XR4
ISINDE000GQ2XR40
Date issued 24/08/2023
Strike 21
Maturity 20/12/2024 (162 Days)
Parity 1 : 1
Emission price 21.77
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 27.08
Lowest since issue 20.79

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - hospital administration and engineering (64.3%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (35.7%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (72.4%), North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%) and Africa (1.6%).
Sector
-
More about the company

Ratings for Fresenius SE & Co. KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius SE & Co. KGaA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.24 EUR
Average target price
37.26 EUR
Spread / Average Target
+27.42%
Consensus